Midatech Pharma Plc P/L
Qual é o P/L de Midatech Pharma Plc?
O P/L de Midatech Pharma Plc é N/A
Qual é a definição de P/L?
A razão entre preço e lucro é a razão entre o preço das ações de uma empresa e o lucro por ação da empresa, calculado ao longo de doze meses.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/L de empresas na Setor Health Care em LSE em comparação com Midatech Pharma Plc
O que Midatech Pharma Plc faz?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Empresas com p/l semelhantes a Midatech Pharma Plc
- UMT United Mobility Technology AG tem P/L de N/A
- Alberton Acquisition tem P/L de N/A
- Evergold tem P/L de N/A
- Evergold Corp tem P/L de N/A
- Teladoc Health tem P/L de N/A
- TRU Precious Metals tem P/L de N/A
- Midatech Pharma Plc tem P/L de N/A
- Rite Aid tem P/L de N/A
- OCL Iron and Steel tem P/L de N/A
- Power Projects tem P/L de N/A
- MAS Gold tem P/L de N/A
- Freshlocal Solutions tem P/L de N/A
- Woodbridge Ventures tem P/L de N/A